Combination Therapy
Approved for: NSCLC
PD-L1
Pembrolizumab (Keytruda) approved Combination Therapy for non-small cell lung cancer (NSCLC) with the biomarker PD-L1.
It is used: Alone as first-line treatment in patients whose cancer has the PD-L1 protein and does not have a mutation in the EGFR gene or ALK gene.
